Tetracycline Pill — Competitive Intelligence Brief

Tetracycline Pill (Tetracycline Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Tetracycline Pill (Tetracycline Pill) — National Cheng-Kung University Hospital. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tetracycline Pill TARGET	Tetracycline Pill	National Cheng-Kung University Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Omadacycline Injection	Omadacycline Injection	Wake Forest University Health Sciences	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tobramycin once a day	Tobramycin once a day	Oslo University Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tigecycline antimicrobial-lock solution	Tigecycline antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)
DoxyPEP	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class